Have a feature idea you'd love to see implemented?
Let us know!
RNAC Cartesian Therapeutics Inc
Price (delayed)
$22.1
Market cap
$472.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.28
Enterprise value
$400.19M
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic
Highlights
RNAC's gross profit has soared by 109% QoQ and by 11% YoY
RNAC's revenue has surged by 109% since the previous quarter and by 11% year-on-year
The company's debt has shrunk by 57% YoY but it rose by 42% QoQ
Key stats
What are the main financial stats of RNAC
Market
Valuations
Earnings
Shares outstanding
21.38M
Market cap
$472.55M
Enterprise value
$400.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.4
Revenue
$54.1M
EBIT
-$247.38M
EBITDA
-$244.51M
Free cash flow
-$65.12M
Per share
Balance sheet
Liquidity
EPS
-$5.28
Free cash flow per share
-$3.89
Book value per share
-$5.7
Revenue per share
$3.24
TBVPS
$17.91
Total assets
$347.74M
Total liabilities
$449.2M
Debt
$14.87M
Equity
-$101.46M
Working capital
$98.67M
Debt to equity
-0.15
Current ratio
4.78
Quick ratio
4.7
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-451.9%
Gross margin
100%
Net margin
-424.5%
Operating margin
-90.5%
Return on assets
-86.3%
Return on equity
N/A
Return on invested capital
-202.7%
Return on capital employed
-76.9%
Return on sales
-457.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAC stock price
How has the Cartesian Therapeutics stock price performed over time
Intraday
-0.36%
1 week
1.84%
1 month
37.1%
1 year
-35.94%
YTD
6.87%
QTD
37.1%
Financial performance
How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$54.1M
Gross profit
$54.1M
Operating income
-$48.99M
Net income
-$229.65M
Gross margin
100%
Net margin
-424.5%
RNAC's gross profit has soared by 109% QoQ and by 11% YoY
RNAC's revenue has surged by 109% since the previous quarter and by 11% year-on-year
RNAC's operating margin has soared by 71% from the previous quarter and by 7% YoY
The company's net margin has surged by 57% QoQ
Growth
What is Cartesian Therapeutics's growth rate over time
Valuation
What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
6.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.4
The company's EPS has surged by 62% YoY and by 35% QoQ
The company's equity rose by 13% QoQ
RNAC's revenue has surged by 109% since the previous quarter and by 11% year-on-year
RNAC's P/S is 81% lower than its last 4 quarters average of 35.1 and 74% lower than its 5-year quarterly average of 26.1
Efficiency
How efficient is Cartesian Therapeutics business performance
The company's return on sales has surged by 56% QoQ
Cartesian Therapeutics's ROIC has increased by 40% from the previous quarter
The return on assets has increased by 26% since the previous quarter
Dividends
What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAC.
Financial health
How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 23% less than its total liabilities
Cartesian Therapeutics's total assets has soared by 149% YoY and by 7% from the previous quarter
The quick ratio has soared by 60% QoQ and by 17% YoY
The company's debt is 115% higher than its equity
Cartesian Therapeutics's debt to equity has plunged by 128% YoY and by 67% from the previous quarter
The company's debt has shrunk by 57% YoY but it rose by 42% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.